# ECOG-ACRIN EA8231 (NCT06524544)

> A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06524544
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Unresectable Urothelial Carcinoma
- Interventions: Biospecimen Collection; Carboplatin; Cisplatin; Computed Tomography; Docetaxel; Gemcitabine; Magnetic Resonance Imaging; Paclitaxel; Pembrolizumab; Questionnaire Administration; Sacituzumab Govitecan
- Enrollment: 320
- Primary outcome: Overall survival (OS)

## Indexed commentary on ECOG-ACRIN EA8231 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 2
- X threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=ecog-acrin-ea8231-nct06524544